gut microbiota
Modifying the microbiota could influence multiple sclerosis progression and provide new therapeutic targets.
Gut microbes adapt to exercise demands, favoring energy production over bacterial diversity.
MaaT Pharma’s venture marks an innovative and hopeful chapter in the ongoing effort to fight neurodegeneration.
Targeting TudS could be a potential therapeutic approach for treating C. difficile infections.
Each Fusobacterium nucleatum population has unique traits and distribution patterns across body sites and conditions such as colorectal cancer and Crohn’s disease.
Gut microbiota-produced bile acids can be used as therapeutic targets for multiple sclerosis.
Probiotic supplementation improves sports performance by enhancing nutrient absorption, immune function, and endurance while reducing anxiety and gastrointestinal symptoms.
At the upcoming 13th edition of the Probiotics, Prebiotics, and New Food Congress in Rome, Professor Emma Allen-Vercoe, PhD from the University of Guelph (Canada), will present groundbreaking research on…
Targeting E. lenta or boosting neutrophil function may lead to new treatment strategies for bronchiectasis and related lung diseases.
Nutrient competition is the main mechanism of C. difficile inhibition, hinting at the potential for targeted therapies with probiotics instead of traditional FMT.
